NVS - Novartis AG
| Previous close | 89.27 |
| Open | 89.36 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's range | 88.65 - 89.36 |
| 52-week range | 69.91 - 93.65 |
| Volume | 1,721,446 |
| Avg. volume | 2,262,080 |
| Market cap | 204.299B |
| Beta (3Y monthly) | 0.55 |
| PE ratio (TTM) | 16.91 |
| EPS (TTM) | 5.27 |
| Earnings date | N/A |
| Forward dividend & yield | 2.83 (3.17%) |
| Ex-dividend date | 2019-03-04 |
| 1y target est | 99.50 |
- Zacks•8 hours ago
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
- Zacks•10 hours ago
Is a Beat in the Cards for Novartis' (NVS) Q2 Earnings?
Investors will focus on regular top- and bottom-line numbers along with pipeline updates when Novartis (NVS) reports second-quarter results.
- Zacks•16 hours ago
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
- Zacks•18 hours ago
Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
- Zacks•2 days ago
J&J Falls Amid Reports of Criminal Probe Into Talcum Powder
The U.S. Justice Department is reportedly pursuing a criminal investigation as to whether J&J (JNJ) lied about the possible cancer risk associated with its talcum powder.
- Motley Fool•5 days ago
What Happened in the Stock Market Today
On a record day for the major benchmarks, Illumina issued a warning, and Novartis and Amgen reported the failure of an Alzheimer's drug.
- Zacks•5 days ago
Amgen & Novartis' Alzheimer Studies End in Another Failure
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
- Zacks•5 days ago
Aimmune Down on Negative ICER Review on Allergy Candidate
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
- MarketWatch•6 days ago
Amgen and Novartis drop Alzheimer's-prevention study after patients worsened
Amgen Inc. and Novartis AG announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions. "An assessment of unblinded data during a regular pre-planned review identified worsening in some measures of cognitive function," the companies said in a joint announcement. "The sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk." The phase 2/3 study, performed in conjunction with Banner Alzheimer's Institute, was testing the BACE1 inhibitor CNP520, or umibecestat, which is an amyloid-focused drug. Biogen Inc. failed in testing of an amyloid-focused drug earlier this year, leading some to predict that focusing on the sticky protein found in the brain could be a losing route to a drug for the debilitating neurodegenerative disease. "We still believe amyloid plays an important but complex role in Alzheimer's disease," Amgen executive David Reese said in Thursday's announcement. Novartis shares were down 1.5% in after-hours trading Thursday, while Amgen shares were not moving after the announcement.
- Zacks•6 days ago
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
- Zacks•7 days ago
Glaxo's Two-Drug HIV Pill Dovato on Par with Three-Drug Pill
Glaxo's (GSK) phase III study, evaluating the efficacy of switching to Dovato from a three-drug TAF based regimen, meets the primary endpoint.
- Motley Fool•7 days ago
The 10 Biggest Healthcare Stocks
How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.
- Zacks•7 days ago
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
- Zacks•8 days ago
Novo Nordisk Reports Encouraging Data From Hemophilia Studies
Novo Nordisk (NVO) reports data on Concizumab and Refixia for the treatment of hemophilia.
- Zacks•8 days ago
Bayer-J&J Announce Positive Xarelto Data in Children with VTE
Bayer's (BAYRY) Xarelto, in the phase III EINSTEIN-Jr study in pediatric patients, shows a similar low risk of VTE or blood clots compared to current standard anticoagulation therapy.
- Zacks•8 days ago
Roche Reveals New Hemlibra Data, Extends Spark Merger Deadline
Roche (RHHBY) presents new positive data on Hemlibra, reinforcing its efficacy and safety. Moreover, the deadline of the impending merger with Spark has been extended.
- Zacks•8 days ago
Aerie Completes Enrollment Under Rhopressa Study in Japan
Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.
- Zacks•14 days ago
Incyte Out-Licenses INCMGA0012 Rights in China to Zai Lab
Incyte (INCY) inks a licensing deal with Zai Lab to develop and commercialize INCMGA0012 for hematology and oncology indications in Greater China.
- Zacks•15 days ago
Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx
Puma Biotech (PBYI) files an sNDA for the nod of Nerlynx in combination with Xeloda to treat patients with HER2-positive metastatic breast cancer, having failed two or more prior lines of treatments.
- Zacks•15 days ago
Alnylam Submits MAA in Europe for RNAi Therapeutic Givosiran
Alnylam (ALNY) submits Marketing Authorization Application to the EMA for givosiran in development for the treatment of acute hepatic porphyria.
- Zacks•15 days ago
AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label
AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.
- Zacks•16 days ago
Roche's Tecentriq Gets CHMP Recommendation for Breast Cancer
Roche (RHHBY) announced that its immuno-oncology drug, Tecentriq, was recommended for approval by the CHMP for triple-negative breast cancer.
- Zacks•16 days ago
Atara Reports Initial Data for Multiple Sclerosis Candidate
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
- Motley Fool•16 days ago
3 Small-Cap Biotech Stocks That Soared Last Week
It was a great week for these three stocks, but can they continue climbing?
- Reuters•16 days ago
Lonza fills portfolio hole by buying Novartis drug bottling plant
Lonza Group is buying a drug bottling plant from Novartis in northern Switzerland as the Swiss drug ingredients maker fills a gap in its offering for drugmakers seeking to outsource production. Novartis is selling the so-called "fill and finish" facility because its production lines had been underutilised. Lonza has been building up its drug products services business for three years and has been weighing whether to buy a factory from a rival where it can put the finishing touches on injectible medicines, or build such a facility itself like it is doing now in Visp, Switzerland.
